Glenmark Pharmaceuticals Ltd on Monday (November 10) said its wholly-owned subsidiary, Glenmark Specialty S.A., announced that the National Medical Products Administration (NMPA) of China has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of Allergic Rhinitis (AR) in adults and children.

The approval covers moderate to severe seasonal allergic rhinitis in adults and pediatric patients aged six years and older, and moderate to severe perennial allergic rhinitis in adults and pediatric patients aged twelve years and older.

The approval was granted with zero supplementation requests, marking an important milestone in Glenmark’s respiratory pipeline. The company said the approval reflects continued progress in advancing innovative and differentiated therapies for pati

See Full Page